Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT-Reference-Cited by-同舟云学术

Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT

Published:2018-03-14 Issue:4 Volume:32 Page:e13225
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Florman Sander¹^ORCID,Vincenti Flavio²,Durrbach Antoine³,Abouljoud Marwan⁴,Bresnahan Barbara⁵,Garcia Valter Duro⁶,Mulloy Laura⁷,Rice Kim⁸,Rostaing Lionel⁹,Zayas Carlos¹⁰,Calderon Kellie¹¹,Meier-Kriesche Ulf¹¹,Polinsky Martin¹¹,Yang Lingfeng¹¹,Medina Pestana Jose¹²,Larsen Christian P.¹³

Affiliation:

1. Recanati/Miller Transplant Institute; Mount Sinai Medical Center; New York NY USA

2. Departments of Medicine and Surgery; University of California; San Francisco CA USA

3. Department of Nephrology; University Hôpital of Bicêtre; Le Kremlin-Bicêtre France

4. Department of Surgery; Henry Ford Hospital; Detroit MI USA

5. Department of Nephrology; Medical College of Wisconsin; Milwaukee WI USA

6. Renal and Pancreas Transplant Department; Hospital Dom Vicente Scherer; Porto Alegre Brazil

7. Department of Medicine; Georgia Regents University; Augusta GA USA

8. Baylor University Medical Center; Dallas TX USA

9. Department of Nephrology and Organ Transplantation; University Hospital and INSERM U563; IFR-BMT; Toulouse France

10. Department of Surgery; Piedmont Hospital; Atlanta GA USA

11. Bristol-Myers Squibb; Lawrenceville NJ USA

12. Department of Internal Medicine; Hospital do Rim; São Paulo Brazil

13. Department of Surgery; Emory University Transplant Center; Atlanta GA USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Transplantation

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ctr.13225/fullpdf

Reference38 articles.

1. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression;Narayanan;Transplantation,2013

2. The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression;Gralla;Clin Transplant,2014

3. Reduced racial disparity in kidney transplant outcomes in the United States from 1990 to 2012;Purnell;J Am Soc Nephrol,2016

4. Kidney;Hart;Am J Transplant,2016

5. Disparities in kidney transplant outcomes: a review;Gordon;Semin Nephrol,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney transplantation: the recipient;Living Donor Organ Transplantation;2024

2. Risks and ways of preventing kidney dysfunction in drug-induced immunosuppression in solid organ recipients;Russian Journal of Transplantology and Artificial Organs;2022-10-20

3. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs;Immunopharmacology and Immunotoxicology;2021-08-20

4. Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients;American Journal of Transplantation;2020-11-24

5. Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction;PLOS ONE;2020-10-15